A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial
Phase 3 trial found 70% infection rate in newly diagnosed multiple myeloma patients receiving elranatamab and daratumumab, indicating need for infection monitoring and prophylaxis.
Key Points
Evaluate infection rates and safety in patients with newly diagnosed multiple myeloma receiving elranatamab and daratumumab.
Phase 3 open-label trial with two treatment arms
Patients received elranatamab with daratumumab and lenalidomide or other therapy
Safety and infection profiles monitored during treatment.
70.3% of patients experienced infections, primarily early in treatment
18.9% had grade 3 infections; no grade 4 infections reported
IgG levels <400 mg/dL observed in 83.8% of patients.